Searchable abstracts of presentations at key conferences in endocrinology

ea0081p472 | Thyroid | ECE2022

Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome

Gambale Carla , Matrone Antonio , Contartese Lea , Prete Alessandro , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

ea0084ps1-03-22 | Thyroid Cancer CLINICAL 1 | ETA2022

Low risk differentiated thyroid carcinoma (DTC) can be safely treated with thyroidectomy alone: real-life experience in a medium-long term follow-up

Faranda Alessio , Gambale Carla , Prete Alessandro , Contartese Lea , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: Since 2006 according to the European consensus for the management of patients with DTC, in tumors ≤ 1 cm, treatment with thyroidectomy alone without 131I treatment was suggested. Therefore, in our institution, we applied this suggestion in clinical practice, although prospective studies were not still available. Aim of this study is to evaluate the rate of the events occurring in a medium-long term follow-up.Patients and Meth...

ea0084ps3-14-125 | Thyroid Cancer CLINICAL 2 | ETA2022

Lymph nodes metastases in differentiated thyroid cancer patients: understanding their impact on the clinical outcome

Matrone Antonio , Gambale Carla , Contartese Lea , Prete Alessandro , Faranda Alessio , Molinaro Eleonora , Elisei Rossella

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

ea0084ps1-03-21 | Thyroid Cancer CLINICAL 1 | ETA2022

Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines

Contartese Lea , Gambale Carla , Prete Alessandro , Puleo Luciana , Cappagli Virginia , Lorusso Loredana , Agate Laura , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...

ea0084ps1-03-20 | Thyroid Cancer CLINICAL 1 | ETA2022

Changes in clinical status after second 131I treatment in patients with differentiated thyroid cancer (dtc) not cured with the initial treatment

Gambale Carla , Matrone Antonio , Bottaro Valeria , Prete Alessandro , Faranda Alessio , Contartese Lea , Bianchi Francesca , Torregrossa Liborio , Basolo Fulvio , Molinaro Eleonora , Elisei Rossella

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...